Doctors construct a new pill for patients with high blood pressure in existing medications as “Gamechanger” and “The Victory of Science”.
Globally, more than 1.3 billion people suffer from high blood pressure. In half of them, high blood pressure or resistance to existing treatments is not controlled. They face a much greater risk of heart attack, stroke, kidney disease and early death.
Now a new drug – Baxdrostat has been shown in experiments to reduce blood pressure dramatically in people whose levels remain dangerously high despite taking many medications.
The results of the BAXHTN study, which included 796 patients from 214 clinics all over the world, showed that after 12 weeks, patients who took a hypertension of their blood pressure at about 9-10 mm (millimeter of mercury, the blood pressure measurement unit) saw more fake-a significant decrease enough to reduce heart risk.
About four of every 10 patients taking the drug – 1MG (39.4 %) or 2MG (40 %) once a day in the form of a disk – they reached healthy blood pressure levels, compared to less than two of every 10 (18.7 %) on the imaginary medicine.
Details of the penetration against stubborn blood pressure at the European Society for Heart Diseases in Madrid, the world’s largest conference in the world. Results from the experiment, sponsored by Astrazneca, were published simultaneously in the New England Medicine Journal.
“I have never seen blood pressure cuts of this size with a drug,” said the lead researcher Professor Brian Williams, head of medicine at the University of California in Los Angeles.
“I think this can be Gamechanger in the way we are close to controlling or difficult to control blood pressure. The results indicate that this drug can help up to half a billion people worldwide.”
The penetration took decades of research to achieve it.
Blood pressure is severely affected by a hormone called aldosterone, which helps the kidneys regulate the balance of salt and water. Some people produce a lot of aldosterone, causing the body to stick to salt and water. Dysfunction in the aldosterone leads to high blood pressure and makes it difficult to control.
Treating the Aldosterone defect has been a major goal of research over many years, but so far it has been impossible to achieve. Baxdrostat works by preventing the production of aldosterone, directly treating this driver for high blood pressure.
“The development of this drug is in fact a victory for a scientific discovery,” Williams told reporters at Madrid.
“Aldosterone is a driver known for high blood pressure, but for decades, scientists have struggled to prevent it in an accurate way. Baxdrostat is one of the first treatments that do this selectively, which indicates a meaningful BP [blood pressure] Discounts in uncontrolled or resistance blood pressure. “
Historically, it has been reported that the richest western countries have increased high levels of high blood pressure. However, to a large extent due to changing meals, the numbers of people with high blood pressure have become much higher in the eastern and low -income countries. more than Half of the affected people live in AsiaIncluding 226 million people in China and 199 million in India.
After promoting the newsletter
Professor Paul Leson, cardiologist and professor of cardiovascular medicine at the University of Oxford, who has not participated in the experiment, said the birth control pills can become an “additional valuable treatment” to treat high blood pressure.
“For many years, we had medications that are able to prevent aldosterone, but they are not at least at least the levels of aldosterone, so patients may still suffer from the harmful effects of the material.
“Baxdrostat … is a single version of a new set of medications that work differently, and reduces directly from the levels of aldosterone.
“More importantly, the experiment was conducted in many countries and included men and women, as well as patients with different ethnic backgrounds. This helps to ensure that the results are related to the group of patients we see with blood pressure problems.”
Separately, doctors were told in Madrid that JAB, which runs the cholesterol that is managed twice a year, has the ability to convert heart care.
The new experiments data presented at the conference proposed Leqvio, also known as Minisiran It was made by Novartis, helped patients achieve their cholesterol goals faster than other treatments. Patients have also suffered from muscle pain, which is a common side effect of statin, and drugs that reduce cholesterol.